Zacks Investment Research on MSN
Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?
It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 26.4% in that time frame, outperforming the S&P 500. But investors have to be ...
A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...
Stocktwits on MSN
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys
Sarepta Therapeutics, Inc. (SRPT) on Tuesday said that the U.S. Food and Drug Administration (FDA) has approved dosing in a ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...
When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen | ...
FDA approves dosing in Sarepta's ENDEAVOR Cohort 8 to test sirolimus with Elevidys in non-ambulant Duchenne patients, ...
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After the ...
The first milestone was hit in July, earning Arrowhead a $100 million payment. Sarepta made the payment by transferring $50 million in Arrowhead shares and paying the rest in cash, using proceeds from ...
The financing exercise at Sarepta Therapeutics continues as uncertainty remains for the company’s flagship gene therapy Elevidys. The Massachusetts biopharma has reached an agreement with some ...
Sarepta Therapeutics reported strong Q4/2023 performance, with $365.1M in net product revenue, up 55% from the previous year. ELEVIDYS, despite not meeting its primary endpoint in the Phase III trial, ...
(Reuters) -Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and weak forecast for its top selling gene therapy raised concerns ...
The Food and Drug Administration won’t sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won’t cause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback